|
Oct 12
|
Indivior price target lowered to $16 from $20 at Craig-Hallum
|
|
Oct 11
|
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...
|
|
Oct 10
|
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
|
|
Oct 10
|
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook
|
|
Oct 10
|
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
|
|
Oct 7
|
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
|
|
Jul 26
|
Indivior reaches $86 million opioid settlement with 16 US states
|
|
Jul 25
|
Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates
|
|
Jul 25
|
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame
|
|
Jul 25
|
Indivior Announces Q2 2024 Financial Results
|
|
Jun 18
|
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and...
|
|
Apr 4
|
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?
|
|
Dec 31
|
Those who invested in Indivior (LON:INDV) three years ago are up 118%
|
|
Sep 7
|
Indivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market Value
|